Can you share a case of a pediatric patient with AD who required intensification of therapy with a systemic, immunotherapeutic agent? What were the specific triggers for deploying a type 2 cytokine-signaling protein inhibitor such a dupilumab?

Can you share a case of a pediatric patient with AD who required intensification of therapy with a systemic, immunotherapeutic agent? What were the specific triggers for deploying a type 2 cytokine-signaling protein inhibitor such a dupilumab?

Can you share a case of a pediatric patient with AD who required intensification of therapy with a systemic, immunotherapeutic agent? What were the specific triggers for deploying a type 2 cytokine-signaling protein inhibitor such a dupilumab?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Mark Lebwohl, MD

Mark Lebwohl, MD

Professor and Chairman, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York USA